Indegene launches new center in London

USFDA grants Priority Review for new indication of finerenone for patients with common heart failure

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure

Financial Times names Indegene among high-growth companies in Asia-Pacific 2025

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products

RedHill Biopharma to submit FDA-approved Talicia for UK marketing authorisation

Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes

Shilpa Biologicals partners with mAbTree Biologics AG for a novel immunooncology asset

This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation

Strides Pharma global to acquire 100% stake in Amextel

Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products

Philips and Medtronic partner to upskill 300+ clinicians in structural heart imaging in India

Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India

MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies

Indegene launches AI platform Cortex

This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain

Bayer files for approval of finerenone in heart failure in Japan

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure